Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17410801 | 0.83 | EGFR (0.60) | EGFRPIK3CAPIK3CDTDO2MAPT | |
| SCHEMBL29891394 | 0.83 | EGFR (0.60) | EGFRPIK3CAPIK3CDTDO2MAPT | |
| SCHEMBL8641138 | 0.78 | EGFR (0.64) | EGFRIMPDH2PIK3CAPIK3CDTDO2 | |
| SCHEMBL1771613 | 0.75 | EGFR (0.60) | EGFRIMPDH2PIK3CAPIK3CDTDO2 | |
| SCHEMBL277541 | 0.75 | EGFR (0.60) | EGFRPDGFRBPDGFRAIMPDH2PIK3CA | |
| SCHEMBL277540 | 0.75 | EGFR (0.60) | EGFRIMPDH2PIK3CAPIK3CDTDO2 | |
| SCHEMBL18618545 | 0.75 | EGFR (0.60) | EGFRIMPDH2PIK3CAPIK3CDTDO2 | |
| SCHEMBL21936740 | 0.75 | EGFR (0.60) | EGFRIMPDH2PIK3CAPIK3CDTDO2 | |
| SCHEMBL1403684 | 0.75 | EGFR (1.00) | EGFRIMPDH2TDO2MAPTKDM4E | |
| SCHEMBL8207570 | 0.75 | EGFR (0.60) | EGFRIMPDH2PIK3CAPIK3CDTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640095-A | Diaryl amine derivative containing aliphatic carboxyl and preparation method and application thereof | 山东大学 | 2023-08-25 | — | — | CN | claimed |
| CN-115417825-A | Five-membered or six-membered fused ring pyrimidine cyclopropyl naphthalene derivative and preparation method and application thereof | 山东大学 | 2022-12-02 | — | — | CN | claimed |
| CN-119490461-A | Trifluoromethyl substituted quinazolinone compound, preparation method and application | 平顶山学院 | 2025-02-21 | — | — | CN | disclosed |
| CN-115417825-B | Five-membered or six-membered fused ring pyrimidine cyclopropyl naphthalene derivative and preparation method and application thereof | 山东大学 | 2024-06-28 | — | — | CN | disclosed |
| CN-116640095-A | Diaryl amine derivative containing aliphatic carboxyl and preparation method and application thereof | 山东大学 | 2023-08-25 | — | — | CN | disclosed |
| CN-115417825-A | Five-membered or six-membered fused ring pyrimidine cyclopropyl naphthalene derivative and preparation method and application thereof | 山东大学 | 2022-12-02 | — | — | CN | disclosed |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| CN-107892684-B | Quinazoline derivatives, pharmaceutical compositions thereof, and use as medicaments | 锦州奥鸿药业有限责任公司 | 2020-05-26 | — | — | CN | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | EGFR 455/4885PDGFRB 1845/4885PDGFRA 1567/4885 |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885PDGFRB 382/4885PDGFRA 242/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885PDGFRB 117/4885PDGFRA 74/4885 |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GRIN2C, TPMT | EGFR 4386/4885PDGFRB 4034/4885PDGFRA 3872/4885 |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | EGFR 4386/4885PDGFRB 4034/4885PDGFRA 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.